PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Directorate Changes and Notice of Results
RNS Number : 1851P
Advanced Oncotherapy PLC
08 June 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

8 June 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

 

Directorate Changes

Notice of results

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, today announces the following changes to its Board of Directors.

 

Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han,  and Dr Yuelong Huang (all Non-Executive Directors of the Company), will step down from the Board and not seek re-election at the Company's upcoming Annual General Meeting ("AGM") which is expected to be held in July 2020. Once these Board changes become effective in July 2020, the Board will decrease from 12 members to eight members and will comprise of three executive directors and five non-executive directors.

 

The audited results for the year ended 31 December 2019 are expected to be announced on or around 29 June 2020. The annual report and accounts will be published shortly thereafter and posted to shareholders together with the notice of AGM.

 

Dr Mike Sinclair, Executive Chairman of Advanced Oncotherapy, commented:

 

"On behalf of the Board, I would like to thank Gabriel, Peter, Allen and Yuelong for their strategic counsel and insight to Advanced Oncotherapy over the years. As valued Board members, they have helped Advanced Oncotherapy to progress to a leading position as a technology disruptor in proton therapy, and we wish them all the best in their future endeavours."

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 (0) 20 3328 5656



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUBSKRRKUNRAR
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close